argenx SE (ARGX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Amsterdam, Netherlands. वर्तमान CEO हैं Timothy Van Hauwermeiren.
ARGX के पास है IPO तिथि 2017-05-18, 1,599 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $51.26B.
Argenx SE is a biotechnology company headquartered in Amsterdam, Netherlands, focused on developing innovative therapies for autoimmune diseases across the United States, Europe, Japan, China, and other global markets. The company's lead product, efgartigimod, targets multiple autoimmune conditions including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris, with a pipeline of additional candidates such as empasiprubart and ARGX-119 addressing conditions like motor neuropathy and amyotrophic lateral sclerosis. Argenx has established strategic partnerships with major pharmaceutical companies including AbbVie, Zai Lab, and LEO Pharma, along with collaborations with leading academic institutions and biotech firms to advance its research and development efforts. The company leverages proprietary platforms and technologies, including its SIMPLE ANTIBODY technology, to discover and develop novel therapeutic antibodies with applications in immunology and oncology.
